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Lower respiratory tract infections, such as infections caused by influenza A viruses, are
a constant threat for public health. Antivirals are indispensable to control disease caused
by epidemic as well as pandemic influenza A. We developed a novel anti-influenza A
virus approach based on an engineered single-domain antibody (VHH) construct that
can selectively recruit innate immune cells to the sites of virus replication. This protective
construct comprises two VHHs. One VHH binds with nanomolar affinity to the conserved
influenza Amatrix protein 2 (M2) ectodomain (M2e). Co-crystal structure analysis revealed
that the complementarity determining regions 2 and 3 of this VHH embrace M2e. The
second selected VHH specifically binds to the mouse Fcγ Receptor IV (FcγRIV) and
was genetically fused to the M2e-specific VHH, which resulted in a bi-specific VHH-
based construct that could be efficiently expressed in Pichia pastoris. In the presence
of M2 expressing or influenza A virus-infected target cells, this single domain antibody
construct selectively activated the mouse FcγRIV. Moreover, intranasal delivery of this
bispecific FcγRIV-engaging VHH construct protected wild type but not FcγRIV−/− mice
against challenge with an H3N2 influenza virus. These results provide proof of concept
that VHHs directed against a surface exposed viral antigen can be readily armed with
effector functions that trigger protective antiviral activity beyond direct virus neutralization.
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INTRODUCTION
Influenza A virus infections are a major recurrent cause of seasonal respiratory tract infections.
The best way to prevent influenza disease is considered to be vaccination. However due to the
accumulation of point mutations in the viral hemagglutinin (HA) and neuraminidase (NA) genes,
human influenza vaccines need to be reformulated and administered regularly based on the
prediction of the circulating strains (1). The variable effectiveness and the long manufacturing
timeline encourage the development of more broadly protective vaccines. Antivirals, such as
oseltamivir and baloxavir marboxil, have been licensed for the prophylaxis and treatment of
uncomplicated influenza, but the risk of selecting drug resistant viruses limits their widespread
use (2, 3).
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The 23 amino acid residues long M2 ectodomain (M2e) is
highly conserved among the different influenza A virus subtypes
and thus represents an attractive target for broadly protective
prophylactic vaccine strategies as well as for antibody-based
antiviral biologicals [reviewed in Saelens (4)] (4, 5). Various
studies using different vaccine formats have demonstrated that
M2e-based vaccination can provide broad protection in animal
models of influenza A and that this protection is antibody
mediated (6–9). Next to vaccines, a therapeutic intervention
with an intravenously administered recombinant human IgG1
monoclonal antibody directed against the M2 N-terminus was
found to reduce the symptoms in human volunteers that had
been infected with an H3N2 virus (10). Furthermore, this phase
2a trial showed that the antibody treatment was associated
with a trend toward reduced viral shedding from the nasal
mucosa, and no anti-M2e escape mutants could be detected.
Finally, intravenous administration of engineered, so called bi-
specific T cell engagers that comprise a M2e-specific single chain
variable fragment that is linked to a CD3ε-specific single chain
variable fragment, could protect mice against an otherwise lethal
influenza A virus challenge (11).
Fc gamma receptor (FcγR) interactions are essential for the
protective activity of M2e-specific antibodies (12–14). FcγRs are
type I membrane proteins that are expressed on different innate
immune cells, including macrophages, neutrophils, natural killer
cells and dendritic cells (15, 16). In mice, FcγRs are characterized
by the presence of an immunoreceptor tyrosine-based activation
motif (ITAM) in the cytoplasmic portion of the common γ chain
that is associated with the activating FcγRI, FcγRIII and FcγRIV,
or by an immunoreceptor tyrosine-based inhibitionmotif (ITIM)
in the cytoplasmic portion of the inhibitory FcγRIIb (17–19).
These receptors differ in their affinities for the different IgG
isotypes (16, 20). Previously, we have shown that protection by
M2e-specific mouse IgG1 requires FcγRIII while IgG2a isotypes
can protect by any of the three activating FcγRs (13).
Since the reported discovery of heavy chain-only antibodies
in camelids in 1993, recombinant single domain proteins
comprising the variable domain of these antibodies (VHHs
also known as Nanobodies R©) have been used in numerous
therapeutic applications (21). In the context of viral infections,
various virus-neutralizing VHHs have been described that can
interfere with different steps in the viral life cycle (22). Due to
their outstanding stability and solubility, as well as their small
size (∼15 kDa), ease of production and formatting flexibility, they
are highly versatile building blocks for the development of new
antivirals. Next to a direct antiviral effect, VHHs can also easily be
formatted (e.g., by generating Fc fusions) to recruit host effector
functions (23). These features, combined with the possibility
to deliver therapeutic VHHs into the lung environment, and
maintained stability after prolonged storage, make VHH-based
anti-influenza biologicals especially attractive for epidemic as
well as pandemic preparedness plans (24–27).
In this study we explored a new strategy to engage host cell
effector functions to combat influenza A. This strategy is based
on a tail-to-head genetic fusion of two VHHs, one that selectively
binds to FcγRIV and a second one that is specific for M2e.
The resulting bi-specific construct can be efficiently expressed in
Pichia pastoris cells and protects mice against an otherwise lethal
influenza A virus infection by simple intranasal delivery.
MATERIALS AND METHODS
Cell Lines and Culture Conditions
HEK293T cells (a gift from Dr M. Hall, University of
Birmingham, Birmingham, UK) and HEK293T cells stably
transfected with influenza M2 (28) were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% of fetal calf
serum, 2mM of L-glutamine, 0.4mM of Na-pyruvate, non-
essential amino acids, 100 U/ml of penicillin and 10µM
amantadine for the M2 expressing HEK cells. Madin-Darby
canine kidney (MDCK) cells were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% of fetal calf
serum, 2mM of L-glutamine, non-essential amino acids and 100
U/ml of penicillin. Mf4/4 cells (an immortalized cell line of spleen
macrophages derived from C57BL/6 mice) were grown in RPMI
1640 medium, supplemented with 10% of fetal calf serum, 2mM
of L-glutamine, 0.4mM of Na-pyruvate, non-essential amino
acids, 50mM 2-mercaptoethanol, 25mM Hepes and 100 U/ml
of penicillin (29). Cloning of FcγR-ζ constructs, the generation
of FcγR-ζ BW5147 reporter cells and the culture conditions were
similar as reported previously (30, 31).
Production of Recombinant Mouse FcγRIV
Protein
Recombinant FcγRIV protein was produced by transient
transfection of subconfluently grown FreesStyleTM293-F cells
(ThermoFisher scientific) with pCAGGs expression vectors
encoding the ectodomain of FcγRIV (amino acids 1-201) coupled
to a C-terminal 6XHis tag. Recombinant FcγRIV protein was
purified from the supernatant 6 days after transfection, using a
1ml HisTrap HP column (GE Healthcare). Fractions containing
FcγRIV protein were pooled and concentrated with a Vivaspin
column (5 kDa cutoff, GE Healthcare) and then further purified
by gel filtration on a Superdex 75 column. Fractions containing
FcγRIV protein were pooled and concentrated. Purity was
evaluated by SDS-PAGE followed by Coomassie blue staining.
Isolation of M2e-Binding, VHH-Displaying
Phages
A llama was immunized 6 times at weekly intervals
subcutaneously with 150 µg M2e-tGCN4 (28) in the presence
of Gerbu LQ#3000 adjuvant. Immunizations and handling of
the llama were performed according to directive 2010/63/EU
of the European parliament for the protection of animals used
for scientific purposes and approved by the Ethical Committee
for Animal Experiments of the Vrije Universiteit Brussel
(permit No. 13-601-1). Five days after the last immunization,
blood was collected and lymphocytes were prepared. Total
RNA was extracted and used as template for the first strand
cDNA synthesis with oligodT primer. The VHH encoding
sequences were amplified from the cDNA and cloned into
the PstI and NotI sites of the phagemid vector pMECS. In
this vector, the VHH coding sequence is followed by a linker,
an HA- and 6xHis tag (AAAYPYDVPDYGSHHHHHH).
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Electro-competent E.coli TG1 cells were transformed with the
recombinant pMECS vector resulting in a VHH library of about
108 independent transformants. A library of VHH-presenting
phages was obtained after infection with VCS M13 helper
phages. Two different panning strategies were used. In the
first strategy, phages were added to 20 µg of immobilized
M2e-tGCN4 in panning round 1 and 20 µg of human H3N2
peptide (SLLTEVETPIRNEWGCRCNDSSD) in panning round
2. In the second strategy, phages were first added to 25 × 106
HEK293T cells to deplete potential binders to determinants
on these cells. The unbound phages were next added to 25 ×
106 HEK293T cells stably transfected with influenza M2, to
enrich for M2-specific phages. To avoid internalization of the
target antigen, all steps were performed at 4◦C. After washing,
retained phages were eluted by pH elution with TEA-solution
(14% triethylamine (Sigma) pH 10) for 10min. A solution of 1M
Tris-HCl pH 8 was used to lower the pH of the eluted phage
solution. The enrichment relative to panning on the negative
control antigen, was determined by infecting TG1 cells with
10-fold serial dilutions of the phages after which the bacteria
were plated on LB agar plates with 100µg/ml ampicillin and
1% glucose.
Isolation of FcγRIV-Binding,
VHH-Displaying Phages
The FcγRIV specific VHHs were isolated form a library that was
part of a study described elsewhere by Deschacht et al. (32).
In brief, a llama was immunized six times at weekly intervals
with 108 immature murine bone marrow-derived dendritic cells.
A library of VHH-presenting phages was obtained as described
above. FcγRIV specific VHHs were enriched after three panning
rounds on 20 µg of immobilized FcγRIV protein.
Periplasmic ELISA Screen to Identify M2e-
and FcγRIV-Specific VHHs
After panning, individual pMEC colonies were randomly selected
for further analysis by ELISA for the presence of M2e-
and FcγRIV-specific VHHs in their periplasm. To prepare
periplasmic extract, individual colonies were inoculated in 2ml
of terrific broth (TB) medium with 100µg/ml ampicillin in
24-well deep well plates. After 5 h incubation isopropyl β-D-1-
thiogalactopyranoside (IPTG) (1mM) was added to induce VHH
expression. After overnight incubation at 37◦C, bacterial cells
were pelleted and resuspended in 200 µl TES buffer (0.2M Tris-
HCl pH 8, 0.5mM EDTA, 0.5M sucrose) and incubated at 4◦C
for 30min. An osmotic shock was induced by adding 300 µl of
water. After 1 h incubation at 4◦C followed by centrifugation, the
periplasmic extract was collected. VHH-containing periplasmic
extracts were then tested for binding to either M2e-tGCN4 (28),
human H3N2 M2e peptide (SLLTEVETPIRNEWGCRCNDSSD)
or recombinant mouse FcγRIV protein. Briefly, wells of
microtiter plates were coated overnight with either 100 ng
M2e-tGCN4, 100 ng mouse FcγRIV protein, bovine serum
albumin (BSA, Sigma-Aldrich) at 4◦C or 100 ng human H3N2
M2e peptide at 37◦C. The coated plates were blocked with
5% milk powder in phosphate buffered saline (PBS) and
100 µl of the periplasmic extract was added to the wells.
Bound VHHs were detected with anti-HA mAb (1/2000, MMS-
101P Biolegend) followed by horseradish peroxidase (HRP)-
linked anti-mouse IgG (1/2000, NXA931, GE Healthcare). All
periplasmic fractions, which resulted in OD450 values of the
antigen coated wells that were at least two times higher than
the OD450 values obtained in BSA coated wells, were selected.
DNA of the selected colonies was isolated using the QIAprep
Spin Miniprep kit (Qiagen) and sequenced using the primer
MP057(5
′
-TTATGCTTCCGGCTCGTATG-3
′
).
VHH Expression in Pichia pastoris
The VHH encoding sequence was amplified by PCR using the
following forward and reverse primer (5
′
-GGC GGG TAT CTC
TCG AGA AAA GGC AGG TGC AGC TGC AGG AGT CTG
GG-3
′
) and (5
′
- CTA ACT AGT CTA GTG ATG GTG ATG
GTG GTG GCT GGA GAC GGT GAC CT GG-3
′
). The PCR
fragments were then cloned between the XhoI and SpeI sites in
the pKai61 expression vector [described by Schoonooghe et al.
(33)]. In the vector, the VHHs sequences containing a C-terminal
6XHis tag sequence are under control of the methanol inducible
AOX1 promotor and in frame with a modified version of the
S. cerevisiae α-mating factor prepro signal sequence. The vector
contains a Zeocine resistance marker for selection in bacteria as
well as in yeast cells. The vectors were linearized by PmeI and
transformed in the P. pastoris strain GS115 using the condensed
transformation protocol described by Lin-Cereghino et al. (34)
After transformation, the yeast cells were plated on YPD plates
(1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) dextrose,
and 2% (w/v) agar) supplemented with zeocin (100µg/ml)
for selection.
VHH Production and Purification
The transformed P. pastoris clones were first analyzed for
VHH expression in 2ml cultures. On day one, 2–5 clones of
each construct were inoculated in 2ml of YPNG medium (2%
pepton, 1% Bacto yeast extract, 1.34% YNB, 0.1M potassium
phosphate pH 6, 1% glycerol) with 100µg/ml Zeocin (Life
Technologies) and incubated at 28◦C for 24 h. The next day,
the cells were pelleted by centrifugation and the medium was
replaced by YPNM medium (2% pepton, 1% Bacto yeast extract,
1.34% YNB, 0.1M potassium phosphate pH 6.0, 1% methanol).
Cultures were incubated at 28◦C and 50 µl of 50% methanol
was added at 16, 24, and 40 h. After 48 h, the supernatant was
collected and the presence of soluble VHHs in the supernatant
was verified using SDS-PAGE and subsequent Coomassie Blue
staining. Production was scaled up (300ml) for the transformants
with the highest levels of VHH in the medium. Growth and
methanol induction conditions and harvesting of medium were
similar as mentioned above for the 2ml cultures. The secreted
VHHs in the medium were precipitated by ammonium sulfate
(NH4)2SO4 precipitation (80% saturation) for 4 h at 4◦C. The
insoluble fraction was pelleted by centrifugation at 20,000 g and
resuspended in 10ml binding buffer (20mM NaH2PO4 pH 7.5,
0.5M NaCl and 20mM imidazole pH 7.4). The VHHs were
purified from the solution using a 1ml HisTrap HP column (GE
Healthcare). Bound VHHs were eluted with a linear imidazole
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gradient starting from 20mM and ending at 500mM imidazole
in binding buffer over a total volume of 20ml. VHH containing
fractions were pooled and concentrated with a Vivaspin column
(5 kDa cutoff, GE Healthcare) and then further purified by gel
filtration (Superdex 75) in PBS buffer. Fractions containing VHH
were again pooled and concentrated. Purity was evaluated by
SDS-PAGE followed by Coomassie blue staining.
Enzyme-Linked Immunosorbent Assay
Wells of microtiter plates were coated overnight with either 100
ng M2e-tGCN4, 100 ng BM2e-tGCN4, 100 ng M2e peptide or
100 ng mouse FcγRIV protein. The coated plates were blocked
with 5% milk powder in phosphate buffered saline (PBS) and
dilution series of the VHHs were added to the wells. In the M2e
ELISA, bound VHHs were detected with mouse anti-Histidine
Tag antibody (MCA1396, Abd Serotec) followed by horseradish
peroxidase (HRP)-linked anti-mouse IgG (1/2000, NXA931, GE
Healthcare). In the ELISA with coated recombinant FcγRIV
protein, binding was detected with a HRP conjugated rabbit anti-
camelid VHH antibody (A01861-200, GenScript). After washing
50 µl of TMB substrate (Tetramethylbenzidine, BD OptETA)
was added to every well. The reaction was stopped by addition
of 50 µl of 1M H2SO4, after which the absorbance at 450 nM
was measured with an iMark Microplate Absorbance Reader
(Bio Rad).
Crystallization of M2e-VHH-23m in
Complex With M2e Peptide
For crystallization, the purified M2e-VHH-23m was
concentrated to 20 mg/ml. The M2e peptide was added in
a 1.2 times excess. Crystallization screens were set up in sitting
drop vapor diffusion at 20◦C. Crystals grown in the Jenna Classic
screen, in 30% ethanol, 10% PEG6000, 100mM Na acetate
were cryoprotected using fluorosilicone and flash frozen in
liquid nitrogen. X-ray data were collected at the i03 beamline of
the Diamond Light Source synchrotron facility and processed
using XDS.47
The structure of the M2e-VHH-23m-M2e peptide complex
was solved using the structure of another nanobody (PDB code
5HGG) as search model for molecular replacement, using the
Phaser program from the CCP4 crystallographic software suite
(35, 36). The M2e-VHH-23m model was built automatically
using Autobuild from the Phenix crystallographic software suite
(37). The initial model was further built manually in Coot and
refined using phenix.refine and Refmac (38–40). Data collection
parameters, as well as processing and refinement statistics are
shown in Table 1. The crystal structure has been deposited in
the Protein Data Bank (PDB) and is available with accession
code 6S0Y.
Docking
All water molecules, the ligand, and chain B of the nanobody
crystal structure were manually deleted from the pdb-text file.
The emptied structure was subjected to a local minimization
with the GROMOS96 (43B1 parameter set) implementation
within Swiss-PdbViewer 4.1.0 (41), and polar hydrogens were
added. The peptide-ligand VETPIRNEWG was 3D-drawn with
TABLE 1 | Data collection statistics and refinement parameters.
Data collection
Synchrotron Diamond Light Source
Beamline i03
Wavelength, Å 0.97965
Data processing
Space group P 21 21 2
Cell parameters, Å (α=β=γ=90◦ ) 57.47 94.76 53.06
Resolution, Å (outer shell) (c) 53.06–1.80 (1.83–1.80)
Total reflections 35827 (17918)
No. of unique reflections 27557 (1359)
Completeness 99.97 (100)
Multiplicity 13.0 (13.2)
Rpim, % 4.4 (66.6)
CC1/2, % 99.8 (57.1)
<I/σ (I)> 11.0 (1.1)
Mosaicity, ◦ 0.063◦
Refinement
Resolution range, Å 47.38–1.81
No. of reflections 25859
Percentage observed 99.96
Rcryst,(a) % 18.69
Rfree,(b) % 22.53
RMS
Bonds, Å 0.01
Angles, ◦ 1.66
Ramachandran Plot
Most favored, % 95.28
Additionally allowed, % 4.72
Disallowed, % 0
PDB code 6S0Y
(a) Rcryst = Σ (|Fobs |–|Fcalc |)/Σ |Fobs |, Fobs and Fcalc are observed and calculated structure
factor amplitudes.
(b) Rfree as for Rcryst using a random subset of the data excluded from the refinement.
(c) Data in brackets are for the highest resolution shell.
Avogadro 1.2.0 (42) and minimized with the built-in united force
field. The AutoDockTools 1.5.6 suite (43) was used for pdbqt-
format conversions and grid-box determination. The grid-box
size was x = 22, y = 30 and z = 20 centered at x = 1.9, y =
9.7 and z = 8.3. Docking was performed with Smina (44, 45)
with exhaustiveness set at 128. Visualization was with PyMOL
2.3.0 (46).
Isothermal Titration Calorimetry
M2e-VHH-23m was dialyzed overnight against PBS buffer and
concentrated using Amicon Ultra 3 kDa cut off centrifugal filter
devices. The M2e peptide was resuspended in PBS at a stock
concentration of 3mM, and diluted in PBS to 300µM. Titrations
comprised 26 × 1.5 µL injections of peptide (300µM) into the
protein (30µM), with 90 s intervals. An initial injection of ligand
(0.5 µL) was made and discarded during data analysis. The data
were fitted to a single binding site model using the Microcal LLC
ITC200 Origin software provided by the manufacturer.
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Ala Scan Mutagenesis
HEK293T cells were transiently transfected with Flag-tagged
M2 wild type (WT) and M2e Ala scan mutants. 24 h after
infection the cells were detached, washed and blocked. Cells
were stained with 20µg/ml M2e VHH-23m or 20µg/ml F-
VHH-4 and subsequently fixed with 2% paraformaldehyde. After
permeabilization (10× permeabilization buffer diluted in double-
distilled water; eBioscience), cells were stained with mouse anti-
Histidine tag antibody (MCA1396, Abd Serotec) and rabbit
anti-Flag tag antibody (F7425, Sigma-Aldrich). Binding of the
primary antibodies was revealed with donkey anti-mouse IgG
coupled to Alexa Fluor 647 (1/600; Invitrogen) and donkey
anti-rabbit IgG coupled to Alexa Fluor 488 (1/600; Invitrogen).
The median fluorescence intensity (MFI) of the cells was
determined with an LSRII HTS flow cytometer (BD) and was
calculated by subtracting the median fluorescence of binding
of M2e-VHH-23m or F-VHH-4 to transfected cells from the
median fluorescence of untransfected cells bound by M2e-VHH-
23m or F-VHH-4.
VHH Binding to Influenza A Virus Infected
Cells
HEK293T cells were mock-infected or infected with A/Puerto
Rico/8/1934 (H1N1), A/X47 (H3N2), A/Udorn/307/1972
(H3N2) or A/Swine/Ontario (H3N3) at a MOI of 1. Twenty-four
hours after infection the cells were detached, washed and
blocked. Cells were stained with 20µg/ml M2e VHH-23m,
20µg/ml F-VHH-4 or 10µg/ml MAb148. To determine the
affinity of M2e-VHH-23m on infected cells, 1/3 dilution series
of M2e-VHH-23m or F-VHH4 were applied to A/Puerto
Rico/8/1934 (H1N1) infected cells. Subsequently, the cells
were fixed with 2% paraformaldehyde and stained with mouse
anti-Histidine Tag antibody (MCA1396, Abd Serotec) and goat
anti-A/Puerto Rico/8/1934 serum (Biodefense and Emerging
Infections Resources Repository, NIAID, NIH, V314-511-157)
followed by anti-mouse IgG Alexa 488 (Invitrogen) and anti-goat
IgG Alexa 647 (Invitrogen). The median fluorescence intensity
(MFI) was measured on the LSRII-tubes flow cytometer (BD)
and was calculated by subtracting the median fluorescence
of binding of M2e-VHH-23m or F-VHH-4 to infected cells
from the median fluorescence of uninfected cells bound by
M2e-VHH-23m or F-VHH-4.
Plaque Reduction Assay
Different amounts of M2e-VHH-23m (2.5µM, 1.25µM or
0.625µM), 0.333µM MAb37 or sera of mice infected with
A/Puerto Rico/8/1934 (H1N1) virus were incubated for 1 h at
4◦C with 10–20 plaque forming units/well of A/Udorn/307/1972
(H3N2) or A/Puerto Rico/8/1934 (H1N1) virus. After incubation,
the mixture was added to MDCK cells, seeded in a flat
bottom 24-well plate. After 1 h, the cells were overlaid with
an equal volume of 1.2% Avicel RC-591 (FMC Biopolymer)
supplemented with 2µg/ml of TPCK-treated trypsin (Sigma).
Infection was allowed for 2 days at 37◦C in 5% CO2. The overlay
was subsequently removed and the cells were fixed with 4%
paraformaldehyde. Viral plaques were stained with convalescent
mouse anti- A/Puerto Rico/8/34 or A/Udorn/307/72 serum
followed by horseradish peroxidase (HRP)-linked anti-mouse
IgG (NXA931, GE Healthcare). Finally, after washing, the
plaques were visualized with TrueBlue peroxidase substrate
(KPL, Gaithersburg).
VHH Binding to FcγRs Expressing Cells
Human Embryonic Kidney (HEK) 293T cells were transiently
transfected with full length mouse FcγRI (MG50086-CF),
FcγRIIb (MG50030-CY, SinoBiological Inc.), FcγRIII (MG50326,
SinoBiological Inc.) or FcγRIV (MG50036-CF, SinoBiological
Inc.) expression constructs along with the common γ-chain for
the activating FcγRs (MG50935-CF) by polyethylenimine (PEI)-
based transfection. A GFP-reporter plasmid was co-transfected.
FcγRIV-VHH-7m and M2e-VHH-23m were directly labeled
with the Alexa FluorTM 647 antibody labeling kit (A20186,
ThermoFisher scientific). Of the labeled VHHs, 0.2µM or
¼ serial dilution series of the VHHs starting from 0.2µM
were added to the transfected cells or Mf4/4 cells (29).
Fluorescence was measured on an LSRII flow cytometer (BD).
The median fluorescence intensity (MFI) was calculated by
subtracting the median fluorescence of binding of M2e-VHH-
23m or FcγRIV-VHH-7m to transfected cells from the median
fluorescence of untransfected cells bound by M2e-VHH-23m
orFcγRIV-VHH-7m.
Construction of Bispecific VHHs
To construct FcγRIV VHH-M2e VHH, FcγRIV VHH-F VHH,
and FcγRIIIa VHH-M2e VHH bispecific VHHs, we made
use of a GoldenBraid-based cloning strategy (47). The coding
information of FcγRIV-VHH-7m or FcγRIIIa VHH [C28 sdAb,
described by Behar et al. (48)] was amplified with the following
forward (5
′
- GCG ATG CAG GGT CTC ACT TCA AGG CAG
GTG CAG CTG CAG GAG TC-3
′
) and reverse primer (5
′
GGC
GAT GGT GGG TCT CAC TTC ATG AGG AGA CGG TGA
CCT GGG-3
′
) that add specific overhangs for their identity
as N-terminal VHH together with a BsaI and SapI restriction
site. The C-terminal VHHs, M2e-VHH-23m and F-VHH-4 were
amplified with a forward (5
′
-GCG CGA TGC AGG GTC TCA
CTT CAC AGG TGC AGC TGC AGG AG TC-3
′
) and reverse
primer (5
′
-GGG CGA TGG TGG GTC TCA CTT CAA GTC
TAG TGA TGG TGA TGG TGG TGG CTG GAG ACG GTG
ACC TG GG-3
′
) that add specific overhangs for their identity as
C-terminal VHH together with a BsaI and SapI restriction site.
The 15 amino acid long (Gly4Ser)3 linker was generated with the
following forward (5
′
- GCG ATG CAG GGT CTC ACT TCA
TCA GGC GGA GGC GGT AGT GGC GGA GGT GGA TCT
GGA GGC GGC GGT AGT CA GT-3
′
) and reverse primer (5
′
-
GGC GAT GGT GGG TCT CAC TTC ACT GAC TAC CGC
CGCCTCCAGATCCACCTCCGCCACTACCGCCTCCGC
CTG AT-3
′
) that also add a specific overhang together with a
BsaI and SapI restriction site. The PCR amplified fragments were
each assembled in a pUPD2 entry vector by a BsaI restriction and
ligation reaction. Once stored in the pUPD2 vector, the different
parts were assembled together in the pKai61 expression vector
using a T4 DNA ligase and a SapI restriction enzyme which
recognizes the SapI restriction site which was introduced after
ligation into the pUPD2 vector.
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In vitro FcγR Activation Assay
FcγR activation by MAbs 37 and 65 as well as by different
M2e-specific nanobodies was determined using an in vitro FcγR
activation assay (13, 30, 31). Cloning of FcγR-ζ constructs and
the generation of FcγR-ζ BW5147 reporter cells were performed
as reported previously (30, 31). Activation of stably transduced
FcγR-ζ BW5147 reporter cells by immune complexes results
in the production of mouse interleukin-2 (mIL-2), which was
quantified by ELISA (30, 31).
HEK293T cells that were stably transfected with an M2
expression vector (28) were cultured in the presence of 10µM
amantadine. The cells were seeded 1 day before the co-
culture experiment in 96-well flat-bottom plates, pre-coated with
fibronectin purified from human plasma (4µg/ml diluted in
PBS). The next day, serial dilutions of the respective MAbs
or VHH fusion constructs (concentrations as indicated ranging
from 4 to 0.0625µg/ml) were added to the HEK293T-M2 and
incubated for 30min at 37◦C, followed by the addition of 1.5 ×
105 FcγR-ζ BW5147 reporter cells in a total volume of 200 µl
RPMI1640 medium with 10% fetal calf serum per well. Target
cells and reporter cells were incubated overnight at 37◦C in a 5%
CO2 atmosphere to allow mIL-2 production. Supernatants were
analyzed by an anti-mIL-2 sandwich ELISA as described using
the capture MAb JES6-1A12 and the biotinylated detection MAb
JES6-5H4 (BD PharmingenTM, Belgium) (30, 31).
For infection with influenza A/Puerto Rico/8/1934 virus,
Madin-Darby canine kidney (MDCK) cells were seeded in 96-
well flat-bottom plates and infected with influenza PR8 virus
(multiplicity of infection [MOI], 5). After 1 h of incubation at
37◦C, unbound virus particles were removed by washing, and
serial dilutions of the respective MAbs or VHHs (concentrations
ranging from 4 to 0.0625µg/ml) were added and incubated
for 30min at 37◦C, followed by the addition of 1.5 × 105
FcγR-ζ BW5147 reporter cells in a total volume of 200 µl
RPMI1640 medium with 10% fetal calf serum per well. Target
cells and reporter cells were incubated overnight at 37◦C in a
5% CO2 atmosphere to allow mIL-2 production. Supernatants
were analyzed by an anti-IL-2 sandwich ELISA as described
(30, 31). If not indicated otherwise, experiments were performed
in triplicates.
Challenge Experiments in Mice
All experiments were approved by and performed according
to the guidelines of the animal ethical committee of Ghent
University (Ethical applications EC2017-66 and EC2018-12).
Female BALB/c mice and male and female C57BL/6 mice were
purchased fromCharles River (France) and FcγRIV−/− C57BL/6
mice (49) were bred in-house under specified-pathogen-free
conditions. Mice were used at age 6–12 weeks and were SPF-
housed with food and water ad libitum. Mice were anesthetized
with isoflurane for treatment and infection. The mice were
treated 4 h before and 24 h after influenza A virus challenge by
intranasal administration of 50 µg of the bispecific VHHs in
a volume of 50 µl PBS. Mice were challenged with 2xLD50 of
A/X47 (H3N2) influenza virus. Body weight loss was monitored
for 14 days. To determine the lung viral titer, complete lungs
were harvested on day 6 after infection and homogenized in
1ml of PBS with a sterile metal bead on the Mixer Mill MM
200 (Retsch). After clearance by centrifugation at 4◦C, the lung
homogenates were used for virus titration by plaque assay. The
plaque assay was performed as described before, plaques were
stained using convalescent mouse anti-X47 serum followed by
horseradish peroxidase (HRP)-linked anti-mouse IgG (NXA931,
GE Healthcare).
Statistical Analysis
Statistical comparison of the differences in body weight loss
was analyzed as repeated measurements data using the residual
maximum likelihood (REML) as implemented in Genstat v19.
Briefly, a linear mixed model (random terms underlined) of the
form y = µ + experiment + treatment + time +treatment.time
+ mouse.time was fitted to the longitudinal data. The term
mouse.time represents the residual error term with dependent
errors because the repeated measurements are taken in the same
individual, causing correlations among observations. Times of
measurement were set as equally spaced, and the autoregressive
model of order 1 was selected as the best correlation model
based on the Aikake Information Coefficient. Significances
of treatment effects across time (i.e., treatment.time) and of
pairwise differences between treatment effects across time were
assessed by an approximate F-test, of which the denominator
degrees of freedom were calculated using algebraic derivatives as
implemented in Genstat v19.
Survival analysis was performed on the right-censored
survival data obtained for the five treatment groups. Groups were
compared using the nonparametric log-rank test as implemented
in Genstat v19. The two independent experiments were set as
different groupings for a stratified test.
For the statistical analysis of the differences in lung viral titers
a Hierarchical Generalized Linear Mixed Model (HGLMM; fixed
model: poisson distribution, log link; random model: gamma
distribution, log link) as implemented in Genstat v19 (see ref
below), was fitted to the titer data. Treatment, having five levels,
was set as fixed term, while replicate was set as random term.
T statistics were used to assess the significance of treatment
differences compared with the FcγRIV VHH-F VHH set as
reference level (on the log-transformed scale). Estimated mean
values and standard errors were obtained as predictions from the
HGLMM, formed on the original scale of the response variable.
Conservation of the M2 Ectodomain
Sequences in Human H3N2 Influenza A
Viruses
All complete M2 protein sequences of human H2N2 viruses,
human H3N2 viruses and human H1N1 influenza A viruses
circulating between 1933 and 2008 were extracted from the
Influenza Research Database (http://www.fludb.org/) on 3th
May 2019.
RESULTS
Isolation of M2e-Specific VHHs
To generate M2e-specific VHHs a llama was immunized
repeatedly with M2e-tGCN4 protein, a soluble recombinant
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immunogen that mimics the natural tetrameric M2e
conformation, that was previously shown to induce protective
M2e-specific IgG antibodies in mice (28, 50). Five days after
the last immunization, peripheral blood lymphocytes were
isolated from the llama and an immune VHH phagemid
library of about 108 clones was generated. M2e-specific
VHHs were enriched from this library by sequential panning
on immobilized M2e-tGCN4 (round 1) and M2e peptide
(SLLTEVETPIRNEWGCRCNDSSD, corresponding to M2e
of human H3N2 viruses) (round 2). As a second strategy,
M2e-specific VHHs were enriched by panning on HEK293T cells
that stably express M2. Individual phagemid clones enriched
after both panning strategies were randomly selected and
tested for binding to M2e-tGCN4 and M2e peptide in ELISA.
Sequence analysis of the VHH encoding clones which tested
positive for binding to either M2e-tGCN4 or M2e peptide
revealed a low sequence diversity. Two clones (M2e-VHH-23m
and M2e-VHH-66m) isolated with the first, and one clone
(M2e-VHH-10m) isolated with the second panning strategy,
were selected for further characterization. These VHHs had a
cysteine residue at position 50 in the CDR2 and position 100b
in the CDR3 (Kabat numbering), allowing the formation of
an additional stabilizing disulfide bound, and were devoid of
N-glycosylation sequons (Figure 1A) (51). The M2e-specific
VHHs and an irrelevant control F-VHH-4 directed against the F
protein of human respiratory syncytial virus, were subsequently
expressed in Pichia pastoris in a secreted format (52). After
purification from the yeast medium, the epitope specificity
was assessed by ELISA. M2e-VHH-23m and M2e-VHH-66m
bound to M2e-tGCN4 with a relatively high affinity, whereas
M2e-VHH-10m displayed weaker binding (Figure 1B). None
of the VHHs bound to purified recombinant influenza B M2
ectodomain fused to tGCN4, suggesting that the VHHs bind
to M2e. The three selected VHHs bound to immobilized M2e-
peptide in ELISA. Amino-acid residues 10 to 23 of M2(e) display
some sequence diversity (50). We therefore tested binding of the
VHHs to peptide variants that correspond to M2e from A/Brevig
Mission/1918 (H1N1), A/Hong Kong/485/1997 (H5N1) and
A/swine/Belgium/1/1998 (H1N1) (Figure 1B). None of the
purified VHHs bound to these M2e peptides, whereas a control
mouse monoclonal antibody (MAb148) that is specific for
the extremely conserved amino-terminus of M2 (SLLTEVET)
did bind (Figure 1B). This indicates that the isolated VHHs
can bind to M2 expressed by human H2N2, the majority of
human H3N2 strains and the majority of human H1N1 viruses
circulating between 1933 and 2008 but are unlikely to recognize
M2 of currently circulating human H1N1 viruses or most avian
and swine influenza viruses. Remarkably, the isolated VHHs
also failed to bind the H1N1 A/Brevig Mission/1/1918 M2e,
which suggests that Ile11 in M2e contributes substantially to
binding. We selected M2e-VHH-23m to target M2e in the
subsequent experiments.
M2e-Specific VHH Clamps M2e Peptide
Between Its CDR2 and CDR3
We performed isothermal titration calorimetry (ITC)
experiments to determine the binding affinity of M2e-VHH-23m
to the human H3N2 M2e peptide. The data revealed a 1:1
biomolecular association between the VHH and the M2e peptide
with a Kd value of 730 nM (Figure 2). The affinity of the single
domain M2e-VHH-23m is thus over a 1,000-fold lower than
the previously reported affinities for the M2e-specific mouse
monoclonal antibodies MAb65 and MAb37 (13).
To precisely resolve the epitope of M2e-VHH-23m, we
determined the crystal structure of this VHH in complex with
human H3N2 M2e peptide to 1.81 Å resolution (Table 1, PDB
code 6S0Y). M2e-VHH-23m binds the M2e N-terminus as a
linear epitope (Figure 3A, left panel). In the crystal structure,
one M2e peptide interacts with three adjacent M2e-VHH-23m
molecules at three respective interfaces (Figure S1). M2e residues
E6 to N13 bind in a shallow groove formed by CDR3, CDR2
and the main body of the VHH formed by β-strands C, C’,
C”, and F (Interface 1; Figure 3A). As expected, based on the
VHH sequence data, a stabilizing disulfide bridge is observed
between the CDR3 and CDR2 (Figure 3A). Interface 1 includes
hydrogen bonds between the M2e-VHH-23m residues Arg45-
Gln46-Gly47 and M2e residues Glu8 and Thr9, M2e-VHH-23m
residue Cys100b and M2e residue Ile11, and M2e-VHH-23m
residue Glu100 and M2e residues Arg12 and Asn13. In addition,
three hydrophobic contacts are formed: (1) M2e residue Val7
binds a shallow pocket lined by residue Phe37, Val100f and
Trp103, (2) Pro10 stacks against Tyr100d, and (3) the side chain
of M2e residue IIe11 is inserted in a pocket formed by the side
chain of IIe58 of the VHH CDR2, and the backbones of Tyr59
(CDR2), Gly47, Val48 and Ser49 (CDR3). De bottom of the
latter pocket is formed by the stabilizing disulfide bridge between
Cys50 in CDR2 and Cys100b in CDR3 (Figure 3A). In interface
2, M2e residues 14 to 19 lie on a surface formed by CDR2 and
CDR3. The highly conserved M2e Trp15 side chain is inserted
in a deep pocket formed by residues from the 3 CDRs: the side
chains of Ile58 and Tyr97, and backbones of Ile51, Gly56, Thr57,
Asn98, Val99, and Gly100a. In addition, the imidazole NH of
Trp15 is hydrogen bonded to the backbone of Asn98 (Interface
2, Figure 3B).
In the crystals, the M2e peptide contacts three adjacent
molecules in an interaction reminiscent of domain swapping
(53). Closer inspection indeed suggests that ligand swapping
occurs between the M2e peptides bound to symmetry related
molecules in the crystal (Figure S2). Docking experiments using
the VETPIRNEWG M2e peptide show that the Interface 1
and 2 regions of the M2e peptide (residues 6–12 and 14–
19, respectively) can bind a single M2e-VHH-23m molecule
(Figure 3C). This is also supported by ITC experiments
indicating that in solution M2e-VHH-23m and M2e interact
in a 1:1 stoichiometry (Figure 2). To validate the relative
importance of the two binding interfaces in this interaction, we
additionally tested the binding of M2e-VHH-23m to HEK293T
cells expressing M2 protein or M2e Ala-mutants by flow
cytometry (Figure 3D). M2e-VHH-23m did not bind to cell that
were transfected with an M2Ile11Ala or M2Trp15Ala expression
construct, confirming the involvement of interface 1 and 2 in
the interaction with M2e. These findings are also in line with
the observation that M2e-VHH-23m fails to bind the H1N1
A/Brevig Mission/1/1918 M2e peptide, which carries a serine
instead of an isoleucine residue at position 11 (Figure 1B).
Reduced binding to cells expressing M2Val7Ala also concurs
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FIGURE 1 | M2e-specific VHHs and their binding specificities. (A) Predicted amino acid residue sequences of M2e-VHH-23m and M2e-VHH-66m (isolated after
panning on M2e-tGCN4 and human H3N2 M2e peptide) and M2e-VHH-10m (isolated after panning on HEK cells stably expressing M2). Above the sequences the
(Continued)
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FIGURE 1 | Kabat numbering is indicated. The complementarity determining regions (CDR) are boxed. (B) M2e peptide ELISAs. Wells of microtiter plates were
coated with 100 ng M2e-tGCN4, BM2e-tGCN4, or high-performance liquid chromatography (HPLC)-purified M2e peptide. The amino acid residue sequences of the
coated proteins or peptides are depicted above the graphs. Amino acid residues that deviate from the consensus human H3N2 M2e sequence are highlighted in red.
Dilution series of the indicated VHHs and MAb148 (a mouse monoclonal IgG1 that recognizes the M2e N-terminus) were added to the coated plates. Binding was
detected with a mouse anti-His tag MAb, followed by a secondary sheep anti-mouse IgG Ab conjugated to horseradish peroxidase (HRP). Data points represent
averages of triplicates and error bars represent standard deviations.
with the co-crystal structure data which show an interaction of
M2eVal7 with a shallow hydrophobic pocket on the surface of
M1e- VHH-23m (Figure 3A).
M2e-VHH-23m Binds to Infected Cells and
Does Not Neutralize Influenza A Virus
Next we used flow cytometry to determine if M2e-VHH-
m23 could bind to M2e in its natural context, on the
surface of influenza A virus infected cells. HEK293T cells
were infected with A/Puerto Rico/8/1934 (H1N1) (M2e:
SLLTEVETPIRNEWGCRCNGSSD), A/X47 (H3N2) (M2e:
SLLTEVETPIRNEWGCRCNDSSD) or A/Udorn/307/1972
(H3N2) (M2e: SLLTEVETPIRNEWGCRCNDSSD) and were
subsequently immuno-stained with MAb148, M2e-VHH-23m
or F-VHH-4. M2e-VHH-23m could bind to the surface of cells
infected with either of the three viruses with a Kd of 13.63 nM
for influenza A/Puerto Rico/8/1934 (H1N1) infected cells
(Figure 4A). In contrast, and as expected, M2e-VHH-23m failed
to bind to cells infected with A/Swine/Ontario/42729A/2001
(H3N3) (M2e: SLLTEVETPTRNGWECRCSDSSD) virus.
These data confirm that M2e-VHH-23m can bind to M2e
sequences that are similar to the H3N2 M2e consensus sequence,
recognizes the central part of such M2e sequences and that at
least the aspartic acid to glycine substitution at position 21 in
A/Puerto Rico/8/1934 M2 is not essential for binding.
It is known that some anti-M2e antibodies can restrict the
in vitro replication of certain influenza A virus strains such
as A/Udorn/307/1972 and A/Hong Kong/8/1968 but not other
viruses such as A/Puerto Rico/8/1934 and A/WSN/1933 in vitro
(54, 55). To address this issue,M2e-VHH-23m orMAb37, aM2e-
specific IgG1 antibody with in vitro neutralizing activity against
A/Udorn/307/1972, were mixed with 10–20 plaque forming units
(pfu) of A/Puerto Rico/8/1934 or A/Udorn/307/1972 before
infection of MDCK cells (56). As expected, both the plaque
size and number of A/Udorn/307/1972, but not of A/Puerto
Rico/8/1934 were reduced in the presence ofMAb37 (Figure 4B).
However, unlike MAb37, and even at a concentration of 2.5µM
(30µg/ml), M2e-VHH-23m did not affect the number and size
of A/Udorn/307/1972 plaques (Figure 4B).
Isolation of FcγRIV-Specific VHHs
Our next aim was to arm M2e-VHH-23m with a second
VHH that targets one of the activating FcγRs such as
FcγRIV. We focused on this activating FcγR because of its
restricted expression on macrophages, monocytes, neutrophils
and dendritic cells but no other myeloid cell population, and
because of its very high affinity for IgG2a monoclonal antibodies,
which contribute the most protection by non-neutralizing
influenza antibodies in the mouse model (13, 20).
To isolate FcγRIV-specific VHHs a phage library obtained
from a llama that had been immunized with immature
mouse dendritic cells (described by Deschacht et al.) was
enriched for candidate FcγRIV-specific phagemid clones by
three panning rounds using immobilized recombinant mouse
FcγRIV extracellular domain protein produced in HEK293T cells
(32). Of these candidates, FcγRIV-VHH-7m was selected after a
subsequent ELISA screen using the FcγRIV antigen (Figure 5A).
The binding specificity of purified FcγRIV-VHH-7m was
analyzed by flow cytometry using HEK-293 cells that were
transiently transfected with GFP and expression vectors coding
for mouse FcγRI, FcγRIII or FcγRIV together with a plasmid
coding for the common γ-chain, or with an expression vector
coding for the inhibitory FcγRIIb. Concentration-dependent
binding to cells transfected with the mouse FcγRIV plus the
common γ chain was clearly detected (Figure 5B). Only at the
highest concentration tested, FcγRIV-VHH-7m weakly bound
to HEK293T cells that expressed mouse FcγRI, FcγRIIb or
FcγRIII (Figure 5B). Expression of the FcγRs on the surface of
the HEK293T cells was verified by staining with an antibody
directed against the tag attached to the FcγRs (Figure S4).
Clear expression of the mouse FcγRI, FcγRIII and FcγRIV was
detected. Expression of the mouse FcγRIIb was less evident,
therefore no firm conclusions about the binding of FcγRIV-
VHH-7m to the mouse FcγRIIb could be deduced. To evaluate
that FcγRIV-VHH-7m was able to bind to cells that express
endogenous levels of the mouse FcγRIV, we tested its binding to
Mf4/4 cells, a mouse macrophage like cell line (29). Unlike M2e-
VHH-M2e, FcγRIV-VHH-7m bound Mf4/4 cells with a deduced
Kd value comparable to the Kd value for binding to FcγRIV
transfected cells (Figure 5B).
Tail-to-Head Fused FcγRIV- and
M2e-Specific VHHs Selectively and
M2-Dependently Activate FcγRIV
To evaluate the possibility to arm the M2e-specifc VHH with
FcγRIV-dependent effector functions, we genetically fused M2e-
VHH-23m carboxy-terminal of FcγRIV-VHH-7m by means of
a flexible 15 amino acid long (Gly4Ser)3 linker. As controls
M2e-VHH-23m was also fused to a VHH directed against
human FcγRIIIa [described by Behar et al. (48)] and FcγRIV-
VHH-7m was linked to F-VHH4. The resulting constructs were
named FcγRIV VHH-M2e VHH, FcγRIIIa VHH-M2e VHH,
and FcγRIV VHH-F VHH, respectively, and were produced
in transformed Pichia pastoris shake flask cultures (Figure 6A).
FcγRIV VHH-M2e VHH could bind to M2e peptide and coated
soluble FcγRIV protein in ELISA (Figure 6A). Next, we evaluated
the potency of the bispecific constructs to activate individual
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FIGURE 2 | Thermodynamic characterization of the M2e:M2e-VHH-23m interaction. Isothermal titration calorimetry of the Me peptide into M2e-VHH-23m.
FcγRs in vitro, by making use of a co-culture of M2-expressing
cells and a set of reporter cell transfectants, which produce
interleukin 2 upon the activation of a specific FcγR (Figure 6B)
(30). As controls for FcγR activation, we used mouse M2e-
specific MAb 37 (IgG1) and MAb 65 (IgG2a). In the presence
of M2-expressing HEK293T cells, MAb 65 dose-dependently
activated all mouse FcγRs. This is expected as mouse IgG2a
antibodies can bind and activate all mouse FcγRs (16). Only
mouse FcγRIIb and -RIII were activated by MAb37, again in line
with the known binding specificity of mouse IgG1 antibodies
for mouse FcγRs (15). In the presence of M2-expressing cells
FcγRIV VHH-M2eVHH potently activated mouse FcγRIV but
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FIGURE 3 | Molecular details of the M2e-VHH-23m: M2e interaction. (A) Crystal structure of M2e-VHH-23m in complex with the M2e peptide, showing the linear
binding epitope of M2e residues 6–13 binding to a shallow groove on the surface of M2e-VHH-23m (Interface 1). Left: The M2e peptide is shown in cyan stick
representation, the M2e-VHH-23m in green cartoon representation. CDR2 and CDR3 are colored pale and lime green, respectively. Right: Details of the interactions
between M2e residues 6–13 and the residues making up interface 1 on M2e-VHH-23m. (B) Details of the interactions between M2e residues 14–19 and the residues
making up interface 2 on M2e-VHH-23m. Coloring of M2e-VHH-23m as in A, M2e shown in gray stick representation. (C) Docking of the M2e peptide on the crystal
structure of M2e-VHH-23m confirms the ligand swapping hypothesis, showing that M2e binds an extended grove on M2e-VHH-23m comprising both Interface 1 and
Interface 2. Coloring of M2e-VHH-23m as in A, M2e shown in yellow stick representation. (D) Binding of M2e-VHH-23m to M2e Ala scan mutants. HEK293T cells
were transfected with Flag-tagged M2 wild type (WT) and M2e Ala scan mutant expression constructs and subsequently incubated with 20µg/ml of M2e-VHH-23m
or F-VHH-4. After fixation with 2% paraformaldehyde and permeabilization, binding was detected with a mouse anti-Histidine tag antibody and rabbit anti-Fag tag
antibody followed by an anti-mouse IgG Alexa 647 and anti-rabbit IgG Alexa 488, respectively. The median fluorescence intensity (MFI) was calculated by subtracting
the median fluorescence of binding of M2e-VHH-23m or F-VHH-4 to transfected cells from the median fluorescence of non-transfected cells bound by
M2e-VHH-23m or F-VHH-4.
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FIGURE 4 | M2e-VHH-23m bind infected cells and lacks in vitro antiviral activity. (A) HEK293T cells were infected with A/Puerto Rico/8/1934 (H1N1), A/X47 (H3N2),
A/Udorn/307/1972 (H3N2) or A/Swine/Ontario (H3N3) virus. The M2e sequences of the different viruses are shown above each graph, residues that differ from the
(Continued)
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FIGURE 4 | consensus human H3N2 M2e sequence are colored red. Twenty-four hours after infection, the cells were stained with 20µg/ml M2e VHH-23m, 20µg/ml
F-VHH-4 or 10µg/ml MAb148. The A/Puerto Rico/8/1934 (H1N1) infected cells were stained with 1/3 dilution series of M2e-VHH-23m or F-VHH-4. After fixation with
2% paraformaldehyde, infected cells were stained with goat anti-A/Puerto Rico/8/1934 serum followed by anti-goat IgG Alexa 647 and bound VHHs were detected
with a mouse anti-Histidine tag antibody followed by anti-mouse IgG Alexa 488. The mean fluorescence intensity (MFI) was calculated by subtracting the median
fluorescence of binding of M2e-VHH-23m or F-VHH-4 to infected cells from the median fluorescence of uninfected cells bound by M2e-VHH-23m or F-VHH-4. Data
points represent averages of triplicates and error bars represent standard deviations. Results of a representative of 3 repeat experiments is depicted for the binding to
the A/Puerto Rico/8/1934 (H1N1) infected cells, the dissociation constant (Kd), is the average of three independent experiments together with the standard deviation.
The green shading in the histograms corresponds to the binding of M2e-VHH-23m to mock-infected HEK cells. (B) M2e-VHH-23m (2.5, 1.25, or 0.625µM),
0.333µM MAb37 or sera of mice infected with A/Puerto Rico/8/1934 (H1N1) virus were incubated with 10 to 20 plaque forming units/well of A/Udorn/307/1972
(H3N2) or A/Puerto Rico/8/1934 (H1N1) virus and then added to MDCK cells. After 1 h, the cells were overlaid with Avicel supplemented with TPCK-treated trypsin.
The overlay was removed after 2 days, cells were fixed with paraformaldehyde and viral plaques were stained with convalescent mouse anti- A/Puerto Rico/8/1934 or
A/Udorn/307/1972 serum followed by HRP-linked anti-mouse IgG (NXA931, GE Healthcare) and TrueBleu substrate.
not FcγRI, -III, and -IIb. None of the control VHH fusion
constructs activated any of the FcγRs, indicating that specificity
for both M2e and FcγRIV of the VHH fusion constructs was
required. Moreover, activation of the mouse FcγRIV reporter
cells by FcγRIV VHH-M2eVHH was only observed in the
presence of M2 expressing target cells (Figure S5). Potent and
dose-dependent activation of mouse FcγRIV by the FcγRIV
VHH-M2e VHH fusion was also observed when A/Puerto
Rico/8/1934 infected MDCK cells were used as target cells
(Figure 6C). Finally, FcγRIIIa VHH-M2e VHH, but not FcγRIV
VHH-M2eVHH, activated the human FcγRIIIa, the ortholog
of mouse FcγRIV, in the presence of A/Puerto Rico/8/1934
infected targeted cells (Figure 6D). We conclude that the tail-to-
head fusion of the FcγRIV- with the M2e-specific VHHs allows
selective, M2-dependent in vitro activation of the mouse FcγRIV.
Intranasal Administration of Bispecific
FcγRIV VHH-M2e VHH Protects Mice From
a Potentially Lethal Influenza A Virus
Challenge
In a final set of experiments, we explored the protective potential
of FcγRIV VHH-M2e VHH in vivo. SPF-housed female BALB/c
mice were treated intranasally with 50 µg FcγRIV VHH-M2e
VHH 4h before and 24 h after challenge with 2xLD50 of A/X47
(H3N2) influenza virus. As controls, mice were treated with
PBS, 50 µg of FcγRIIIa VHH-M2e VHH or FcγRIV VHH-F
VHH. The mice that had been treated with FcγRIV VHH-M2e
VHH were significantly better protected from body weight loss
and lethality caused by the influenza virus infection compared,
to mice that had been treated with the negative control VHH
fusion constructs, which combine targeting of FcγRIIIa with
M2e-specificity or targeting of RSV-F with FcγRIII-specificity
(Figure 7A). In addition, the protection mediated by FcγRIV
VHH-M2e VHH was associated with a modest but statistically
significant reduction in lung viral titer (Figure 7B). To verify
if the protection by FcγRIV VHH-M2e VHH was mediated by
FcγRIV engagement, wild-type and FcγRIV−/− C57BL/6 mice
were intranasally treated with 50 µg FcγRIV VHH-M2e VHH
or FcγRIIIa VHH-M2e VHH, as negative control, 4 h before and
24 h after challenge with 2xLD50 of A/X47 (H3N2) influenza
virus. While treatment with FcγRIV VHH-M2e VHH could
protect wild-type mice, FcγRIV−/− mice and control-treated
wild-type mice did not survive the virus challenge (Figure 7C).
Moreover, body weight loss after challenge was statistically
significantly reduced in FcγRIV VHH-M2e VHH treated wild-
type mice, compared to FcγRIV−/− mice (p < 0.001). Thus,
selective targeting of mouse FcγRIV with the recombinant two-
domain construct FcγRIV VHH-M2e VHH, can protect mice
against a potentially lethal influenza A virus challenge.
DISCUSSION
Formatting of VHH fragments to develop biologicals to prevent
or treat infectious diseases is a powerful and attractive approach
to develop biologicals with enhanced specificity, activity, half-
life and breadth of protection. Here, VHH formatting was
used to test if arming of a virus surface antigen-specific VHH
with an artificial and selective FcγR activation function can
potentiate its activity to combat viral infections in the absence
of direct virus neutralization. To explore this possibility, we
focused on influenza A M2e as a viral target. This antigen
is conserved among influenza A viruses and is therefore an
attractive target to achieve broad protection. M2e-specific VHHs
were obtained after immunization of a llama with M2e fused
to a heterologous tetramerizing domain, to mimic the natural
quaternary structure of M2, followed by panning onM2e peptide
or cells that stably express M2. We isolated and characterized
in more detail three M2e-specific VHHs. Although several M2e-
specific conventional MAbs have been described in recent years,
to our knowledge, these are the first reported single domain
antibodies that specifically bind to M2e. Recently, a M2-specific
VHH was isolated from a synthetic VHH library by Wei et al.
(57), however their VHH failed to bind to M2e peptide.
We determined the crystal structure of M2e-VHH-23m in
complex with a M2e peptide, that corresponds to the consensus
sequence of human H1N1 viruses that circulated between 1933
and 2008, human H2N2 and H3N2 viruses. This structure
revealed that the M2e antigen is bound by the VHH in an
extended conformation that wraps around two main interfaces
on the VHH. A first interface is a shallow groove formed
by the CDR2 and CDR3 loops and the C, C’, C”, and F
β-strands (Figure 3A). This interface binds the M2e region
spanning residues 6–12, where Val7, Pro10 and Ile 11 bind
hydrophobic patches on the VHH. In addition to three main
chain interactions, the side chains of M2eGlu8 and -Thr9 each
go into an H-bond interaction with the VHH. A second binding
interface is found on the “back” side of the VHH, interacting with
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FIGURE 5 | Characterization of the isolated FcγRIV-specific VHH. (A) The predicted amino acid residue sequence of FcγRIV-VHH-7m, isolated after panning on
recombinant mouse FcγRIV protein of a VHH library derived from a llama immunized with immature mouse dendritic cells. Above the sequences the Kabat numbering
is indicated. CDR1, −2, and −3 are boxed. (B) Flow cytometric analysis showing binding of FcgRIV-VHH-7m and M2e-VHH-23m to HEK 293T cells transiently
transfected with expression vectors coding for mouse FcγRI, FγRIIb, FcγRIII, and FcγRIV along with the common γ-chain for the activating FcγRs and a GFP
expression plasmid. The lower graph depicts binding to Mf4/4 cells. The cells were incubated with fourfold serial dilution of Alexa FluorTM 647 labeled FcγRIV-VHH-7m
or M2e-VHH-23m, starting at a concentration of 0.2µM, binding of the VHHs to the GFP positive cells was analyzed. Data points represent averages of triplicates and
error bars standard deviations.
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FIGURE 6 | Bispecific fusion construct of anti-mouse FcγRIV VHH with M2e-VHH-23m selectively activates FcγRIV in vitro. (A) Schematic representation
of the bispecific VHHs and ELISA on human H3N2M2e peptide and recombinant FcγRIV protein is shown on the right. Wells of microtiter plates were coated with 100 ng
(Continued)
Frontiers in Immunology | www.frontiersin.org 15 December 2019 | Volume 10 | Article 2920
De Vlieger et al. Influenza A Targeting Bispecific Nanobodies
FIGURE 6 | peptide or protein. Dilution series of the bispecific VHH fusion constructs were added to the coated plates. Binding was detected with a mouse anti-His
tag MAb, followed by a secondary sheep anti-mouse IgG Ab conjugated to HRP for the peptide ELISA. In the ELISA with coated recombinant FcγRIV protein, binding
was detected with a HRP-conjugated rabbit anti-camelid VHH antibody. (B) Serial dilutions of the bispecific VHH fusion construct or monoclonal antibodies were
added to HEK293T cells stably transfected with an influenza M2 expression plasmid. Thirty minutes later, FcγR-ζ BW5147 reporter cells were added to the HEK293T
cells. After overnight incubation produced mIL-2 was measured in a sandwich-ELISA, which served as an indicator for the magnitude of FcγR activation. (C) MDCK
cells were infected with A/Puerto Rico/8/1934 (H1N1) virus for 1 h. Unbound virus particles were washed away and serial dilutions of the bispecific VHHs or
monoclonal antibodies were added and incubated for 30min, followed by the addition of the FcγRIV-ζ BW5147 reporter cells (C) or human FcγRIIIa-ζ BW5147
reporter cells (D). After overnight incubation supernatants were analyzed by an anti mIL-2 sandwich ELISA. Data points represent averages of triplicates and error
bars represent standard deviations. The graphs are a representative of one out of three repeat experiments.
residues 14–19 of M2e. This interface contains a well-defined
hydrophobic pocket that captures the side chain of the highly
conserved Trp15. Most avian and swine influenza A viruses, and,
since the 2009 pandemic, also most circulating human H1N1
viruses, have a threonine instead of an isoleucine at position 11 of
M2(e). Threonine is not hydrophobic and would be incompatible
to the VHH’s hydrophobic pocket. This likely explains why M2e-
VHH-23m fails to bind to the tested avian and swineM2e peptide
variants. In contrast to Ile11, M2e-Trp15, which occupies the
second hydrophobic pocket of the VHH, is strictly conserved in
all known influenza A viruses. M2e Ala-scan analysis revealed
that next to Ile11 and Trp15 also substitution of Val7 or Glu14
considerably impairs binding of M2e-VHH-23m. M2eVal7 is
strictly conserved in all influenza A viruses and M2eGlu14 is
highly conserved in human influenza A viruses. Since M2eVal7,
-Ile11, -Glu14, and -Trp15 are highly conserved in all H3N2
influenza A strains, M2e-VHH-23m might have the potential
to recognize the vast majority of these strains. The M2e N-
terminus (SLLTEVET) is highly conserved among all influenza
A viruses and is recognized by some conventional monoclonal
antibodies such as MAb 148 and TCN-032. Despite employing
various panning strategies using avian and swine M2e variants,
we could not yet isolate a VHH that specifically binds the strictly
conserved region in the M2e N-terminus.
Earlier we reported the crystal structures of M2e in complex
with the Fab fragment of two different mouse monoclonal
antibodies (MAb 65 and MAb 148) that recognize partially
overlapping epitopes of M2e (50, 58). In these two crystal
structures, M2e adopted two different conformations. The
epitopes of the MAb 65 and M2e-VHH-23m are highly similar:
they both span the TEVETPIRNEW fragment and in both
M2eIle11 and -Trp15 are important for binding. Nevertheless,
the conformation of the TEVETPIRNEWpart ofM2e in complex
with M2e-VHH-23m is very different from that in complex with
the MAb 65 (Figure S3). This indicates that M2e indeed has
little intrinsic structure and can adopt multiple conformations
dependent on the bound antibody. This flexible nature of theM2e
peptide could explain why it appears to be difficult to isolate a
VHH that recognizes the N-terminal part of M2e. Moreover, due
to the absence of the light chain, VHHs typically bind to concave
epitopes rather than to convex or protruding peptide termini (59,
60). Nevertheless a few VHHs directed against linear peptides
have been described (61, 62). De Genst et al. reported on a VHH
that binds to the C-terminus of the intrinsically disordered a-
synuclein protein with nanomolar range affinity (61). The crystal
structure revealed that this VHH binds the four C-terminal
amino acids of α-synuclein by a narrow pocket formed by its
CDR2 and CDR3. This suggests that it may be possible to isolate
VHHs that specifically bind the highly conserved N-terminus
of M2.
In this study, we also report the isolation of a FcγRIV-specific
VHH from a llama that had been immunized with immature
mouse dendritic cells. This VHH bound to mouse FcγRIV
and showed no cross reactivity with the other FcγRs. To our
knowledge, this is the first report of an FcγRIV-specific VHH.
A fibronectin scaffold protein that could specifically bind to
FcγRIV with high affinity has been reported (63). In addition,
this scaffold protein was able to delay tumor growth in a mouse
model when linked to an anti-tumor antigen-specific single-chain
antibody andmouse serum albumin (to extend the half-life of the
fusion construct).
The bivalent VHH comprising the FcγRIV-specific VHH and
the M2e-specific VHH, could activate the mouse FcγRIV in the
presence of influenza A virus infected cells. Specifically targeting
only FcγRIVmight be an advantage over conventional antibodies
since the activation of the inhibitory FcγRIIb receptor, which
dampens the immune cell activation, is circumvented this way.
In this context, other strategies such as site-directed mutagenesis,
bispecific antibody formats and glycan engineering have been
explored to try to increase Fc binding to activating receptors
and decrease the interaction with the inhibitory receptor FcγRIIb
(64–67). For example, afucosylated antibodies against RSV, Ebola
virus and HIV with enhanced FcγR binding showed enhanced
efficacy in rodent models (67–69).
When administered 4 h before and 24 h after infection, the
bispecific FcγRIV VHH-M2e VHH construct protected wild-
type but not FcγRIV−/− mice against an otherwise lethal
influenza A virus challenge. It is well documented that protection
by M2e-specifc antibodies is FcγR mediated (6–9). We recently
reported that wild type mice treated with an M2e-specific
IgG2a showed significantly less body weight loss after infection
compared with FcγRIV-/- mice, suggesting that FcγRIV could
contribute to protection by M2e-specific IgG2a (13). Here we
show that the selective activation of the mouse FcγRIV with
a bispecific VHH fusion that also binds to M2e is sufficient
to protect mice against a potentially lethal influenza A virus
challenge. Antitumor activity has been reported for bispecific
VHH fusion constructs that consist of a VHH directed against
the human FcγRIIIa (the ortholog of themouse FcγRIV), fused to
either a VHH directed against carcinoembryonic antigen (CEA)
or HER2 (70, 71). In the context of viral infections, it has been
reported that selective engagement of human FcγRIIIa could
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FIGURE 7 | Bispecific fusion construct of a FcγRIV- and M2e-specific VHH protects mice against a potentially lethal influenza A virus infection. (A) Groups of 16
(bispecific VHHs) or 14 (PBS) BALB/c mice were intranasally treated with 50 µg of the bispecific VHHs or PBS 4h before and 24 h after challenge with 2xLD50 of
A/X47 (H3N2) influenza virus. Body weight change (left) and survival (right) were monitored for 14 days. The mean relative changes in body weight together with their
standard errors, are represented. The difference in body weight loss between FcγRIV VHH-M2e VHH and the negative-control groups was statistically significant (***P
< 0.001, REML variance components analysis). The survival rate of the group receiving FcγRIV VHH-M2e VHH was significantly different from FcγRIV VHH-F VHH
control treatment group (***p < 0.001, Log-rank test). (B) To determine the effect on the viral load in the lungs, groups of 13 (bispecific VHHs) or 11 (PBS) BALB/c
mice received 50 µg of the bispecific VHHs or PBS 4h before and 24 h after viral challenge with 2xLD50 of A/X47 (H3N2) influenza virus. On day 6 after infection, the
lungs were harvested and the viral titer was determined by plaque assay. The viral titer of mice FcγRIV VHH-M2e VHH was significantly different compared to mice
that received the FcγRIV VHH-F VHH control treatment (***P < 0.001, unpaired t-test). (C) Groups of 5 wild-type and FcγRIV−/− C57BL/6 mice (male and female
mice) were treated with 50 µg of the bispecific VHHs 4 h before and 24 h after viral challenge with 2xLD50 of A/X47 (H3N2) influenza virus and body weight (left) and
survival (right) were monitored. In the left-hand graph, data points represent means and error bars represent the standard errors of the means. Body weight changes
between FcγRIV VHH-M2e VHH treated wild-type and FcγRIV−/− mice were significantly different (***P < 0.001, REML variance components analysis). The survival
rate of wild-type mice that received FcγRIV VHH-M2e VHH was significantly different from wild-type mice treated with FcγRIIIa VHH-M2e VHH (**P < 0.01, REML
variance components analysis) and FcγRIV−/− mice treated with FcγRIV VHH-M2e VHH and FcγRIIIa VHH-M2e VHH (*P < 0.05, REML variance components
analysis). Data in (A,B) are pooled from 2 independent experiments.
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mediate killing of HIV infected target cells by NK cells (72, 73).
It remains to be investigated whether exchanging the mouse
FcγRIV specific VHH by a human FcγRIIIa specific VHH in
the bispecific fusion construct described here, would be able to
protect against influenza A virus infection in the context of a
human FcγR repertoire. Moreover, the M2e-specific VHH could
be exchanged by a VHH direct against another (conserved) viral
target antigen such as the hemagglutinin stalk domain, since
FcγRs also seem to play an important role in the protection
mediated by anti-stalk antibodies (74, 75).
In summary, we have demonstrated that an intranasally
administered, bi-specific VHH fusion construct that selectively
binds to and activates FcγRIV with one moiety and M2e as
present on infected target cells can protect against influenza
A virus challenge. However, the treated mice still showed
substantial bodyweight loss following challenge whereas
intranasal administration of a M2e-specific IgG2a monoclonal
antibody largely controlled the morbidity following challenge
of the mice (unpublished result). In future studies one could
try to optimize the Fcγ Receptor engaging VHH-fusions by
extending their lung retention, and further increasing the affinity
for both the viral target and the specific FcγR. Finally, when
humanized, formatted M2e-specific VHHs might provide a
new treatment option in the battle against influenza A virus
infections. This approach could also be of interest for other viral
infections. Such VHHs might be especially well suited to prevent
or treat respiratory infections because VHHs can be delivered
directly to the site of infection as inhaled biotherapeutics by
nebulization (27).
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